Keyphrases
Stereotactic Radiosurgery
100%
Radiation Therapy
95%
Overall Survival
58%
Brain Metastases
57%
Tumor
37%
Radiation Oncology
35%
Hippocampal Avoidance
31%
Temozolomide
30%
Local Control
30%
Simulation-free
29%
Phase 1/2 Study
29%
Concurrent Radiation
29%
Disulfiram
29%
Newly Diagnosed Glioblastoma
29%
Melanoma Brain Metastases
29%
Treatment Planning
27%
Non-small Cell Lung Cancer (NSCLC)
22%
Patterns of Care
22%
BRAF mutant
21%
Glioblastoma
20%
American Society
20%
Whole Brain Radiation Therapy
20%
Lung Cancer Brain Metastases
20%
Progression-free Survival
20%
Palliative Radiotherapy
20%
Internal Exposure
19%
NRG Oncology
19%
Stereotactic Body Radiation Therapy
19%
Dose Escalation
19%
Surface Reconstruction
19%
Whole Brain
18%
Oblique Plane
16%
Radiation Oncologist
16%
Confidence Interval
16%
Computed Tomography
16%
Segmentation Method
15%
IDH-mutant Glioma
13%
National Cancer Database
13%
Tumor Segmentation
12%
Plan Generation
11%
Dosimetric Predictors
11%
User Study
11%
Transverse Plane
11%
Limited-stage
11%
In(III)
11%
Whole Brain Radiotherapy
10%
Adaptive Radiotherapy
10%
Magnetic Resonance Imaging
10%
Spine
10%
Treatment Plan
10%
Medicine and Dentistry
Stereotactic Radiosurgery
80%
Radiation Therapy
78%
Brain Metastasis
73%
Overall Survival
56%
Whole Brain Radiotherapy
31%
Radiation Oncology
30%
Bladder
29%
Stereotactic Body Radiation Therapy
29%
Melanoma
29%
Treatment Planning
28%
Non Small Cell Lung Cancer
26%
Neoplasm
25%
Computer Assisted Tomography
24%
Immunotherapy
24%
Magnetic Resonance Imaging
23%
Lung Cancer
19%
Palliative Radiation Therapy
19%
Malignant Neoplasm
15%
Local Therapy
12%
Contouring
12%
Radiation Oncologist
11%
Hippocampus
11%
Chemoradiotherapy
11%
Radiation Necrosis
11%
Prostate Cancer
11%
Hazard Ratio
10%
Radiosurgery
10%
Salvage Therapy
10%
Proportional Hazards Model
9%
Progression Free Survival
9%
Oligoastrocytoma
9%
Veterans Affairs
9%
Muscle Invasive Bladder Cancer
9%
Oligodendroglioma
9%
Diagnosis
9%
Squamous Cell Carcinoma
9%
In Silico
9%
Spine Metastasis
9%
DNA Template
9%
Adaptive Radiotherapy
9%
Oncology
9%
Randomized Clinical Trial
9%
Transitional Cell Carcinoma
9%
Glioblastoma
9%
Isocitrate Dehydrogenase
9%
Bone Metastasis
9%
Supportive Care
9%
Attitude
9%
Small-Cell Carcinoma
9%
Nicotine Withdrawal
9%